Previous 10 | Next 10 |
Agilent (NYSE: A ) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo. More news on: Agilent Technologies, Inc., Avantor, Inc., Axonics Modulation Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
ICON awarded for capabilities and innovations in successful drug development and patient recruitment ICON plc, (NASDAQ: ICLR) a leading global provider of drug and medical device development and commercialisation services, has won Best Contract Research Organisation – Full-S...
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Evercore ISI 2nd Annual HealthCONx Conferen...
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Jefferies 2019 London Healthcare Conference...
Image source: The Motley Fool. ICON (NASDAQ: ICLR) Q3 2019 Earnings Call Oct 24, 2019 , 9:00 a.m. ET Operator Continue reading
ICON Public Limited Company (ICLR) Q3 2019 Earnings Conference Call October 24, 2019 9:00 a.m. ET Executives Steve Cutler - CEO Brendan Brennan - CFO Jonathan Curtain - VP, Corporate Finance and IR Andrew Wald - Barclays Analysts Elizabeth Anderson - Evercore ISI John K...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2019 Q3 earnings Read more ...
Acquisition enhances ICON’s ability to offer customers hybrid trial solutions and site support services ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, ...
Highlights Record net business wins in the quarter of $931 million; a book to bill of 1.31. Quarter 3 reported revenue of $710.4 million. This represents strong year on year growth of 8.5% or 9.5% on a constant currency basis. Adjusted earnings per share attributable to the Gr...
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present at Baird’s 20...
News, Short Squeeze, Breakout and More Instantly...
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 20...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclus...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...